Omega-3 Polyunsaturated Fatty Acids in Patients with Hypertriglyceridemias and Atherosclerosis

Along with increased levels of low-density cholesterol, lipid factors of the risk of cardiovascular complications (CVC) include hypertriglyceridemia, particularly increased plasma levels of remnant particles. Omega-3 polyunsaturated fatty acids (ω-3 PUFA) are essential for normal functioning of cell membranes, retina, nerve tissue, skeletal muscles, etc. Among the large family of fatty acids (FA), eicosapentaenoic (EPC) and docosahexaenoic (DHX) FA are most studied. The beneficial effect of ω-3 PUFA consumption on the cardiovascular system is related with improvement of blood rheology, antiarrhythmic and anti-inflammatory effects, and a decrease in triglycerides. Large randomized studies of ω-3 PUFA (mixed EPC and DHX or only EPC) have demonstrated their efficiency and safety and a capability for reducing the incidence of CVC and sudden death as well as improvement of the prognosis in various patient populations. In the STRENGTH study (combination of omega-3 and statins), no significant decrease in the risk of CVC was achieved in patients with high triglycerides and low high-density lipoproteins. The ω-3 PUFA treatment is regulated by current international Guidelines and Consensuses as a part of combination therapy with statins for reduction of the risk of CVC and correction of pronounced hypertriglyceridemia.

Download Full-text

Omega 3 versus Omega 6 Polyunsaturated Fatty Acids in Cardio-Metabolic Health

10.36502/2020/hcr.6166 ◽

2020 ◽

Vol 1 (2) ◽

pp. 83-100

Author(s):

Halim M ◽

Halim A

Keyword(s):

Fatty Acids ◽

Polyunsaturated Fatty Acids ◽

Meta Analysis ◽

Inflammatory Factors ◽

Cochrane Library ◽

High Density Lipoproteins ◽

Cardiometabolic Health ◽

Omega 3 ◽

Cardiometabolic Diseases ◽

Research Studies

Background: Cardiometabolic diseases like type 2 diabetes, metabolic syndrome, heart failure, and other cardiovascular complications are the leading cause of mortality and morbidity across the globe. These conditions are directly attributed to modifiable behaviors such as sedentary activity, poor diet, excessive consumption of alcohol, or smoking. Efforts aimed towards their prevention and management are, therefore, not only essential in the accomplishment of the healthy populations but also for eliminating the associated cost and health burdens. Dietary change is an important approach to the promotion of cardiometabolic health. Omega 3 (C20–22 ω3) polyunsaturated fatty acids have pleiotropic effects on the functioning of cells, control inflammatory factors, and cellular events in vascular endothelial cells and cardiomyocytes. The hypolipemic, anti-arrhythmic, and anti-inflammatory properties of fatty acids offer cardioprotection. Government agencies and national heart associations recommend increased consumption of omega 3 polyunsaturated fatty acids (PUFA) supplements and fish to prevent cardiometabolic diseases. Purpose of the Study: The purpose of this study is to investigate the role played by ω-3 and ω-6 polyunsaturated fatty acids in promoting cardiometabolic health. Methods: The research study searched databases such as MEDLINE®, Embase, PsycINFO, CINAHL® and the Cochrane Library for relevant research studies evaluating the function/benefits of polyunsaturated fatty acids particularly ω-3 and ω-6 polyunsaturated fatty acids in promoting cardiometabolic functions published between 2011 and 2020. A total of 77 research studies were identified and used in the meta-analysis. Results: Results from the meta-analysis indicated that polyunsaturated fatty acids lower the risk for cardiovascular disease by limiting inflammation of blood vessels, reducing thrombosis, increasing levels of high-density lipoproteins, reducing levels of low-density lipoproteins, and reducing risk factors associated with hypertension. Conclusion: Given the benefits of polyunsaturated fatty acids lower the risk for cardiovascular diseases indicted in the meta-analysis. Therefore, human diets must contain the required amounts of PUFA due to the associated benefits.

Download Full-text

Influence of Probiotic Dietary Supplements Enriched With Omega-3 Fatty Acids on The Dynamics of The Lipid Metabolism of Rats Under Cholesterol Loading

E3S Web of Conferences ◽

10.1051/e3sconf/202124701031 ◽

2021 ◽

Vol 247 ◽

pp. 01031

Author(s):

Irina Khamagaeva ◽

Natalya Zambalova ◽

Aleksandra Tsyzhipova ◽

Aleksey Bubeev ◽

Olga Bogdanova

Keyword(s):

Fatty Acids ◽

Polyunsaturated Fatty Acids ◽

Dietary Supplements ◽

Linseed Oil ◽

Bifidobacterium Longum ◽

Atherogenic Diet ◽

Atherogenic Index ◽

High Density Lipoproteins ◽

Control Group ◽

Omega 3

For the first time, we have studied the influence of polyunsaturated fatty acids on cholesterol metabolizing activity of bifidobacteria. High levels of destruction of cholesterol in the process of cultivation of strain Bifidobacterium Longum DK 100 was noted. Based on the results, the technology of probiotic dietary supplements (DS), enriched with polyunsaturated fatty acids, has been developed. The paper reveals that the introduction of probiotic DS leads to a twofold reduction in total cholesterol in the experimental groups in comparison with the control one, which indicates high effectiveness of DS. It has been observed that against the background of the atherogenic diet, the employment of probiotic DS is accompanied by a significant reduction in triglyceride levels by 37% and 45% in the "linen" and "cedar" groups, respectively, compared to the control group of animals. It has been established that in the blood serum of animals of experimental groups, the level of high-density lipoproteins increases by 45% in "linen" and 40% in "cedar" groups, while low-density lipoproteins decreased by 19% and 23% respectively. With the introduction of probiotic DS with linseed oil, the atherogenic index decreases by 83%, and with the cedar one by 86%. The results confirm the hypocholesterinemic effect of DS during cholesterol loading.

Download Full-text

Dietary omega-3 and -6 polyunsaturated fatty acids affect the composition and development of sheep granulosa cells, oocytes and embryos

Reproduction ◽

10.1530/rep-09-0219 ◽

2010 ◽

Vol 139 (1) ◽

pp. 57-69 ◽

Cited By ~ 79

Author(s):

K E Wonnacott ◽

W Y Kwong ◽

J Hughes ◽

A M Salter ◽

R G Lea ◽

...

Keyword(s):

Fatty Acids ◽

Polyunsaturated Fatty Acids ◽

Granulosa Cells ◽

Differential Effect ◽

Embryo Quality ◽

Ovarian Function ◽

De Novo ◽

Density Lipoprotein ◽

High Density Lipoproteins ◽

Omega 3

The evidence that omega-3 (n-3) and -6 (n-6) polyunsaturated fatty acids (PUFAs) have differential effects on ovarian function, oocytes and embryo quality is inconsistent. We report on the effects of n-3 versus n-6 PUFA-enriched diets fed to 36 ewes over a 6-week period, prior to ovarian stimulation and follicular aspiration, on ovarian steroidogenic parameters and embryo quality. Follicle number and size were unaltered by diet, but follicular-fluid progesterone concentrations were greater in n-3 PUFA-fed ewes than in n-6 PUFA-fed ewes. The percentage of saturated FAs (mostly stearic acid) was greater in oocytes than in either granulosa cells or plasma, indicating selective uptake and/or de novo synthesis of saturated FAs at the expense of PUFAs by oocytes. High-density lipoproteins (HDLs) fractionated from sera of these ewes increased granulosa cell proliferation and steroidogenesis relative to the FA-free BSA control during culture, but there was no differential effect of n-3 and n-6 PUFAs on either oestradiol or progesterone production. HDL was ineffective in delivering FAs to embryos during culture, although n-6 PUFA HDL reduced embryo development. All blastocysts, irrespective of the treatment, contained high levels of unsaturated FAs, in particular linoleic acid. Transcripts for HDL and low-density lipoprotein (LDL) receptors (SCARB1 and LDLR) and stearoyl-CoA desaturase (SCD) are reported in sheep embryos. HDL reduced the expression of transcripts for LDLR and SCD relative to the BSA control. The data support a differential effect of n-3 and n-6 PUFAs on ovarian steroidogenesis and pre-implantation development, the latter in the absence of a net uptake of FAs.

Download Full-text

The Functional Properties of Bread Enriched with Essential Fatty Acids

KnE Life Sciences ◽

10.18502/kls.v7i1.10126 ◽

2022 ◽

Author(s):

Lamazhapova Galina Petrovna ◽

Syngeeva Erzhena Vladimirovna ◽

Zhamsaranova Sesegma Dashievna ◽

Kozlova Tatyana Sergeevna

Keyword(s):

Fatty Acids ◽

Polyunsaturated Fatty Acids ◽

Lipid Profile ◽

Functional Food ◽

Activity Index ◽

Reductase Activity ◽

Essential Fatty Acids ◽

Oxidation Products ◽

High Density Lipoproteins ◽

Omega 3

We developed ω-3-enriched bread by adding a liposomal polyunsaturated fatty acids (PUFAs) concentrate to the bread recipe. We determined that subsequent feeding of the ω-3-enriched bread to experimental animals in the alimentary dyslipidaemia state led to normalisation of the lipid profile of the blood serum, with a decrease in the total cholesterol, triglycerides, and low-density and very lowdensity lipoproteins. The high-density lipoproteins, antioxidants, reduced glutathione and glutathione reductase activity index increased compared to the corresponding indicators in animals with alimentary dyslipidaemia that were fed bread without ω-3. The ω-3-enriched bread diet significantly decreased harmful oxidation products (diene conjugates and malondialdehyde) in the blood plasma, erythrocytes and liver. Therefore, the results suggested that bread enriched with ω-3 fatty acids is a functional food with hypolipidaemic action. The results on the total content of fatty acids in lipids from bread samples prepared according to a standard recipe and bread enriched with concentrate showed that the relative content of omega-3 PUFAs in the fortified bread significantly increased by 3.2 times compared to bread without the addition of concentrate. The additive did not change the consumer qualities of the finished product (taste and smell of the bread). Keywords: alimentary dyslipidaemia, antioxidant effect, bread, functional food, lipid profile, ω-3 polyunsaturated fatty acids

Download Full-text

Stimulating the Resolution of Inflammation Through Omega-3 Polyunsaturated Fatty Acids in COVID-19: Rationale for the COVID-Omega-F Trial

Frontiers in Physiology ◽

10.3389/fphys.2020.624657 ◽

2021 ◽

Vol 11 ◽

Author(s):

Hildur Arnardottir ◽

Sven-Christian Pawelzik ◽

Ulf Öhlund Wistbacka ◽

Gonzalo Artiach ◽

Robin Hofmann ◽

...

Keyword(s):

Fatty Acids ◽

Polyunsaturated Fatty Acids ◽

Cardiovascular Complications ◽

Cytokine Release ◽

Omega 3 ◽

Resolution Of Inflammation ◽

Pufa Supplementation ◽

Inflammatory Reactions ◽

Omega 6 ◽

Single Blind

Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19). SARS-CoV-2 triggers an immune response with local inflammation in the lung, which may extend to a systemic hyperinflammatory reaction. Excessive inflammation has been reported in severe cases with respiratory failure and cardiovascular complications. In addition to the release of cytokines, referred to as cytokine release syndrome or “cytokine storm,” increased pro-inflammatory lipid mediators derived from the omega-6 polyunsaturated fatty acid (PUFA) arachidonic acid may cause an “eicosanoid storm,” which contributes to the uncontrolled systemic inflammation. Specialized pro-resolving mediators, which are derived from omega-3 PUFA, limit inflammatory reactions by an active process called resolution of inflammation. Here, the rationale for omega-3 PUFA supplementation in COVID-19 patients is presented along with a brief overview of the study protocol for the trial “Resolving Inflammatory Storm in COVID-19 Patients by Omega-3 Polyunsaturated Fatty Acids - A single-blind, randomized, placebo-controlled feasibility study” (COVID-Omega-F). EudraCT: 2020-002293-28; clinicaltrials.gov: NCT04647604.

Download Full-text

A randomized, double-blind, placebo-controlled study of polyunsaturated fatty acids efficacy in adolescents with anorexia nervosa

Pharmacotherapy in Psychiatry and Neurology ◽

10.33450/fpn.2020.06.001 ◽

2020 ◽

Vol 36 (2) ◽

pp. 95-106

Author(s):

Agnieszka M. Piróg-Balcerzak ◽

Anna K. Bażyńska ◽

Katarzyna Biernacka ◽

Joanna Brągoszewska ◽

Lidia Popek ◽

...

Keyword(s):

Fatty Acids ◽

Anorexia Nervosa ◽

Polyunsaturated Fatty Acids ◽

Small Sample Size ◽

Small Sample ◽

Female Adolescent ◽

Eating Attitude ◽

Controlled Study ◽

Omega 3 ◽

Eat 26

Objective. Omega–3 polyunsaturated fatty acids (PUFAs) were tested in adolescent depression and in several neurodevelopmental disorders with partial success. Anorexia nervosa (AN) is characterised by deficiencies in fatty food intake and frequent comorbidity, including depressive and cognitive symptoms. Thus supplementation with PUFAs may be beneficial in this group of patients. The aim of the study was to assess whether PUFAs as an add-on treatment is associated with better improvement of body mass index (BMI) and psychopathological symptoms than placebo in patients with AN. Method. 61 female adolescent inpatients with AN were randomly allocated to omega–3 PUFAs supplementation or placebo for 10 weeks. Patients also participated in the behavioural programme and eclectic psychotherapy (treatment as usual, TAU). At baseline and follow-up visits, patients’ BMI and psychopathology were assessed with Clinical Global Impression Scale (CGI), Patient Global Impression Scale (PGI), and Eating Attitude Test (EAT-26). Results. After 10 weeks, both groups showed improvement in all parameters. Improvement in CGI scores was observed greater in placebo vs. PUFA-s group (p = 0.015) while other differences were not statistically significant. Omega–3 PUFAs supplementation appears not to be effective as an add-on treatment in inpatient adolescent girls with anorexia nervosa. Conclusions. The results should be analysed with caution due to small sample size and heterogeneity in TAU. As the TAU turned out to be highly effective, additional therapeutic effect of PUFA might not be visible. Nevertheless, that does not explain the tendency for better improvement in the placebo group.

Download Full-text